CHMP approvals today include ABBV’s Venclyxto* for CLL, ICPT’s Ocaliva† for PBC, and MYL’s generic Truvada: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/10/news_detail_002617.jsp&mid=WC0b01ac058004d5c1 *Approved in US under brand name, Venclexta in Apr 2016 (#msg-121830825). †Approved in US in may 2016 (#msg-122964925).